Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy—an emerging problem and solutions offered by diabetes technology

Endocrine ◽  
2017 ◽  
Vol 56 (1) ◽  
pp. 212-216 ◽  
Author(s):  
A. Pfützner ◽  
D. Klonoff ◽  
L. Heinemann ◽  
N. Ejskjaer ◽  
J. Pickup
Keyword(s):  
Type 2 Diabetes ◽  
Sglt2 Inhibitor ◽  
Inhibitor Therapy ◽  
Diabetes Technology

2220-PUB: Renal Outcomes Associated with Canagliflozin 100mg and with Intensification of SGLT2 Inhibitor Therapy Switching to Canagliflozin 300mg in Patients with Type 2 Diabetes Mellitus in a Real-World Setting: The Renal-WECAN Study

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 2220-PUB
Author(s):  
JUAN J. GORGOJO-MARTINEZ ◽  
MANUEL A. GARGALLO-FERNANDEZ ◽  
ALBA GALDON ◽  
TERESA ANTÓN-BRAVO ◽  
MIGUEL BRITO-SANFIEL ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Sglt2 Inhibitor ◽  
Inhibitor Therapy ◽  
Renal Outcomes ◽  
Real World Setting

1127-P: Real-World Clinical Outcomes Associated with Canagliflozin 100mg and with Intensification of SGLT2 Inhibitor Therapy Switching to Canagliflozin 300mg in Patients with Type 2 Diabetes Mellitus: The Real-WECAN Study

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1127-P
Author(s):  
JUAN J. GORGOJO-MARTINEZ ◽  
MANUEL A. GARGALLO-FERNANDEZ ◽  
ALBA GALDON ◽  
TERESA ANTÓN-BRAVO ◽  
MIGUEL BRITO-SANFIEL ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Clinical Outcomes ◽  
Real World ◽  
Sglt2 Inhibitor ◽  
Inhibitor Therapy ◽  
The Real

scholarly journals Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 8 (1) ◽  
pp. 45 ◽  
Author(s):  
Tamara Y. Milder ◽  
Sophie L. Stocker ◽  
Christina Abdel Shaheed ◽  
Lucy McGrath-Cadell ◽  
Dorit Samocha-Bonet ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Low Dose ◽  
Meta Analysis ◽  
Sglt2 Inhibitor ◽  
Cochrane Library ◽  
High Dose ◽  
Dose Combination ◽  
Inhibitor Combination

Background: Guidelines differ with regard to indications for initial combination pharmacotherapy for type 2 diabetes. Aims: To compare the efficacy and safety of (i) sodium-glucose cotransporter 2 (SGLT2) inhibitor combination therapy in treatment-naïve type 2 diabetes adults; (ii) initial high and low dose SGLT2 inhibitor combination therapy. Methods: PubMed, Embase and Cochrane Library were searched for randomised controlled trials (RCTs) of initial SGLT2 combination therapy. Mean difference (MD) for changes from baseline (HbA1c, weight, blood pressure) after 24–26 weeks of treatment and relative risks (RR, safety) were calculated using a random-effects model. Risk of bias and quality of evidence was assessed. Results: In 4 RCTs (n = 3749) there was moderate quality evidence that SGLT2 inhibitor/metformin combination therapy resulted in a greater reduction in HbA1c (MD (95% CI); −0.55% (−0.67, −0.43)) and weight (−2.00 kg (−2.34, −1.66)) compared with metformin monotherapy, and a greater reduction in HbA1c (−0.59% (−0.72, −0.46)) and weight (−0.57 kg (−0.89, −0.25)) compared with SGLT2 inhibitor monotherapy. The high dose SGLT2 inhibitor/metformin combination resulted in a similar HbA1c but greater weight reduction; −0.47 kg (−0.88, −0.06) than the low dose combination therapy. The RR of genital infection with combination therapy was 2.22 (95% CI 1.33, 3.72) and 0.69 (95% CI 0.50, 0.96) compared with metformin and SGLT2 inhibitor monotherapy, respectively. The RR of diarrhoea was 2.23 (95% CI 1.46, 3.40) with combination therapy compared with SGLT2 inhibitor monotherapy. Conclusions: Initial SGLT2 inhibitor/metformin combination therapy has glycaemic and weight benefits compared with either agent alone and appears relatively safe. High dose SGLT2 inhibitor/metformin combination therapy appears to have modest weight, but no glycaemic benefits compared with the low dose combination therapy.

Discovery of Tofogliflozin, a NovelC-Arylglucoside with anO-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

2012 ◽  
Vol 55 (17) ◽  
pp. 7828-7840 ◽  
Author(s):  
Yoshihito Ohtake ◽  
Tsutomu Sato ◽  
Takamitsu Kobayashi ◽  
Masahiro Nishimoto ◽  
Naoki Taka ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Sglt2 Inhibitor ◽  
Ring System ◽  
Sodium Glucose Cotransporter

3-Oxodapagliflozin as a potent and highly selective SGLT2 inhibitor for the treatment of type 2 diabetes

2014 ◽  
Vol 30 (5) ◽  
pp. 785-793 ◽  
Author(s):  
Shuo Zhang ◽  
Yuli Wang ◽  
Wei Liu ◽  
Yafei Xie ◽  
Yuqiang Liu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Sglt2 Inhibitor

scholarly journals EMPAGLIFLOZIN (SGLT2 INHIBITOR) IN TYPE 2 DIABETES MELLITUS

2017 ◽  
Vol 4 (38) ◽  
pp. 2317-2320
Author(s):  
Mohammed Umar Farooque ◽  
Bharat Bhushan
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Sglt2 Inhibitor
Sign in / Sign up

Export Citation Format

Share Document